Capitation for cardiologists: accepting risk for coronary artery disease under managed care

R L McNamara1, N R Powe, T Shaffer

  • 1Department of Epidemiology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA. rmcnamar@jhsph.edu

Insights

Using clinical factors like disease severity and comorbidity for capitation rates, unlike demographics, better reflects coronary artery disease patient costs. However, significant cost variations remain, posing financial risks for physicians in managed care plans.

Area of Science:

  • Health Economics
  • Medical Care Management
  • Cardiology

Background:

  • Capitated managed care plans may exclude patients with chronic diseases due to high costs.
  • Risk adjustment techniques aim to create equitable capitation rates, including for coronary artery disease (CAD).

Purpose of the Study:

  • To evaluate the impact of using clinical factors versus demographic factors for setting capitation rates for patients with coronary artery disease (CAD).
  • To compare the effectiveness of demographic factors (age, gender) with clinical factors (ICD-9 codes for severity, Charlson index for comorbidity) in predicting healthcare expenditures for CAD patients.

Main Methods:

  • Analysis of a 5% national random sample of the 1992 Medicare population.
  • Comparison of mean annual expenditures for individuals with CAD using demographic factors versus clinical factors for risk adjustment.

Main Results:

  • Mean annual expenditures for CAD patients were over double those of the general Medicare population ($6,944 vs $3,247).
  • Demographic factors (age, gender) resulted in a narrow expenditure range ($6,205-$7,724) for CAD subgroups.
  • Clinical factors (severity, comorbidity) identified wider expenditure ranges ($1,702-$19,959), better reflecting cost variations.
  • Significant expenditure variation persisted within clinical subgroups, with a few patients incurring disproportionately high costs.

Conclusions:

  • Demographic factors alone are insufficient for equitable capitation rate setting, potentially leading to risk selection and financial losses for physicians.
  • Clinical measures improve risk adjustment but do not eliminate the financial risk to physicians due to high-cost outliers.
  • Further strategies are needed to manage financial risks associated with high-expenditure patients in capitated care for chronic diseases like CAD.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...